Ondansetron
Also known as: Zofran
5-HT3 Antagonist | Anti-Nausea On Cycle
Overview
Ondansetron is a selective serotonin 5-HT3 receptor antagonist originally developed and FDA-approved for the prevention of nausea and vomiting caused by chemotherapy, radiation therapy, and surgery. It works by blocking serotonin signaling in both the gut and the brain's chemoreceptor trigger zone, making it one of the most effective and widely prescribed anti-emetics available. In the performance-enhancement and peptide community, ondansetron has become an essential support compound for managing nausea caused by a range of commonly used agents. GLP-1 receptor agonists like semaglutide and tirzepatide are notorious for dose-dependent nausea, particularly during titration phases, and ondansetron is the go-to solution for keeping users compliant with their protocols. It is similarly relied upon for nausea triggered by HCG, nandrolone (Deca/NPP), pramipexole, and various oral compounds that cause gastric distress. The orally disintegrating tablet (ODT) formulation is especially popular because it dissolves on the tongue in seconds and does not require swallowing a pill while actively nauseated.
Key benefits
- Highly effective at controlling nausea and vomiting from a wide range of causes, including GLP-1 agonists, HCG, and nandrolone
- Orally disintegrating tablet (ODT) dissolves on the tongue in seconds, ideal for use during active nausea when swallowing pills is difficult
- Does not cause sedation, extrapyramidal symptoms, or prolactin elevation, unlike dopamine-blocking anti-emetics
- Fast onset of action (15-30 minutes oral, near-immediate for ODT) with reliable 4-8 hour duration
- Well-tolerated with a mild side effect profile at standard doses
- Widely available as an inexpensive generic in multiple formulations
Mechanism of action
Ondansetron exerts its anti-emetic effects through selective antagonism of serotonin 5-HT3 receptors. These receptors are concentrated in two key areas relevant to nausea: the vagal afferent nerve terminals in the gastrointestinal tract and the chemoreceptor trigger zone (CTZ) in the area postrema of the brainstem. When emetogenic stimuli (chemotherapy, medications, gut irritation) cause enterochromaffin cells in the gut to release large amounts of serotonin, this serotonin activates 5-HT3 receptors on vagal afferents, which transmit nausea signals to the brainstem vomiting center. Ondansetron blocks this signaling pathway at both the peripheral (gut) and central (CTZ) level. Unlike dopamine antagonists such as metoclopramide, ondansetron does not block D2 receptors and therefore does not cause extrapyramidal side effects or prolactin elevation, making it a much cleaner anti-emetic for long-term or repeated use. The drug is metabolized hepatically via CYP3A4 and CYP1A2 and is eliminated with a half-life of approximately 4 hours.
Molecular data
- Type
- Carbazole derivative (C18H19N3O)
- Half-life
- ~4 hours
Indications
What the research community uses this compound for, with self-reported effectiveness.
FDA-Approved
Off-Label (Primary Use in PED/Peptide Community)
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 4-8 mg | As needed, up to 3 times daily (max 24 mg/day) | — |
| — | 4-8 mg | 30-60 minutes before the triggering event | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Headache (most frequently reported side effect)
- Constipation (5-HT3 blockade reduces gut motility)
- Fatigue or dizziness
- Dry mouth
Rare side effects
- QT prolongation and cardiac arrhythmias, particularly at doses exceeding 16 mg IV or in patients with pre-existing cardiac conditions or electrolyte imbalances
- Serotonin syndrome when combined with other serotonergic drugs (SSRIs, SNRIs, MAOIs) at high doses
- Hypersensitivity reactions including anaphylaxis (very rare)
- Transient elevations in liver enzymes (typically asymptomatic and self-resolving)
Contraindications
- Known hypersensitivity to ondansetron or other 5-HT3 antagonists
- Congenital long QT syndrome
- Concurrent use of apomorphine (risk of severe hypotension and loss of consciousness)
- Severe hepatic impairment (maximum dose should not exceed 8 mg/day)
Monitoring
- ECG monitoring if used at high doses (>16 mg/day) or in patients with cardiac risk factors
- Electrolytes (potassium, magnesium): hypokalemia or hypomagnesemia can exacerbate QT prolongation
- Liver function: periodic monitoring in patients with hepatic impairment
- Bowel function: constipation is the most common ongoing side effect and may require management with fiber, hydration, or osmotic laxatives
References
Primary literature and clinical-trial data informing this entry.